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Abstract
Background: The objective of this study will be to synthesize the epidemiological evidence and evaluate the validity
of the associations between central nervous system disorders and the risk of developing or dying from cancer.
Methods/design: We will perform an umbrella review of systematic reviews and conduct updated meta-analyses of
observational studies (cohort and case-control) investigating the association between central nervous system disorders
and the risk of developing or dying from any cancer or specific types of cancer. Searches involving PubMed/MEDLINE,
EMBASE, SCOPUS and Web of Science will be used to identify systematic reviews and meta-analyses of observational
studies. In addition, online databases will be checked for observational studies published outside the time frames of
previous reviews. Eligible central nervous system disorders will be Alzheimer’s disease, anorexia nervosa, amyotrophic
lateral sclerosis, autism spectrum disorders, bipolar disorder, depression, Down’s syndrome, epilepsy, Huntington’s disease,
multiple sclerosis, Parkinson’s disease and schizophrenia. The primary outcomes will be cancer incidence and cancer mortality
in association with a central nervous system disorder. Secondary outcome measures will be site-specific cancer incidence and
mortality, respectively. Two reviewers will independently screen references identified by the literature search,
as well as potentially relevant full-text articles. Data will be abstracted, and study quality/risk of bias will be
appraised by two reviewers independently. Conflicts at all levels of screening and abstraction will be resolved
through discussion. Random-effects meta-analyses of primary observational studies will be conducted where appropriate.
Parameters for exploring statistical heterogeneity are pre-specified. The World Cancer Research Fund (WCRF)/American
Institute for Cancer Research (AICR) criteria and the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach will be used for determining the quality of evidence for cancer outcomes.
Discussion: Our study will establish the extent of the epidemiological evidence underlying the associations between
central nervous system disorders and cancer and will provide a rigorous and updated synthesis of a range of important
site-specific cancer outcomes.
Systematic review registration: PROSPERO CRD42016052762
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Background
Cancer caused over 8.8 million deaths worldwide in
2015 and has moved from the third leading cause of
death in 1990 to the second leading cause in 2015 [1, 2].
Similarly, central nervous system disorders are a leading
cause of the disease burden worldwide, substantially
contributing to health loss across the lifespan [3–5].
Population growth and aging are producing a shift in the
global burden of disease from communicable to chronic
non-communicable diseases and from premature
mortality to morbidity [4, 5]. This epidemiological
transition is contributing to a rise in the global burden
of chronic diseases such as central nervous system
disorders and cancer, particularly in low-income regions
[4–6]. In addition, comorbidity or multimorbidity (the
presence of two or more chronic medical conditions in
an individual) represents a paradigm shift from a single
disease-based model to one that focuses on care for
patients with multiple conditions [6–8].
During the past decades, a series of epidemiological
observational studies and meta-analyses have claimed
that central nervous disorders are associated with
increased risk of cancer at several specific sites (e.g. an
increased risk of brain cancer with multiple sclerosis, an
increased risk of breast cancer with schizophrenia, an
increased risk of melanoma with Parkinson’s disease, or
an increased risk of leukaemia and testicular cancer with
Down’s syndrome) [9–17]. At the same time, there is
now epidemiological evidence suggesting a decreased
risk of cancer in certain central nervous system disor-
ders such as Alzheimer’s disease, multiple sclerosis and
Parkinson’s disease [16–26]. In 2013, members of our
review team conducted meta-analyses of cancer inci-
dence in 50 observational studies including more than
570,000 participants from different settings (involving
eight central nervous disorders such as Alzheimer’s
disease, amyotrophic lateral sclerosis, autism spectrum
disorders, Down’s syndrome, Huntington’s disease, mul-
tiple sclerosis, Parkinson’s disease and schizophrenia and
eight site-specific cancers such as brain, breast, colorec-
tal, lung, prostate, testicular cancers, leukaemia and
melanoma) [16]. The main findings were published in
2014, suggesting that the presence of central nervous
system disorders was associated with a decreased risk of
cancer (risk ratio = 0.92; 95% confidence interval (CI) 0.87–
0.98). Similarly, a decreased risk of cancer was detected in
patients with neurodegenerative disorders (0.80; 95% CI
0.75–0.86) and in those with Alzheimer’s disease (0.32; 95%
CI 0.22–0.46), Parkinson’s disease (0.83; 95% CI 0.76–0.91),
multiple sclerosis (0.91; 95% CI 0.87–0.95) and Hunting-
ton’s disease (0.53; 95% CI 0.42–0.67). Patients with Down’s
syndrome had an increased risk of cancer (1.46; 95% CI
1.08–1.96). We did not observe associations between can-
cer and amyotrophic lateral sclerosis or schizophrenia [16].
Many factors might account for these epidemiological
associations, both biological, such as opposing genes and
pathways, and non-biological, such as behaviors, diag-
nostic patterns or medication effects [17, 27, 28].
Because of its biological plausibility, the so-called
‘inverse cancer comorbidity’ in people with central
nervous system disorders has captured the imagination
and efforts of a growing number of scientists and
researchers worldwide [16, 28]. In fact, cancer and
central nervous system disorders share many genes and
biological pathways, and these are often regulated in
different directions [16, 17, 27–29]. However, it is
also possible that some claimed epidemiological asso-
ciations could be caused by chance, confounding and
biases in the published biomedical literature. Potential
biases have been discussed and suggested in the
epidemiology of cancer for multiple risk factors,
biomarkers and prognostic factors, including selective
reporting bias (e.g. favoring the publication of signifi-
cant associations) [30–34].
Past reviews [13–15, 22, 26] have considered some of
the potential associations between cancer and specific
central nervous system disorders in isolation. There is a
need for comprehensive syntheses of all available epi-
demiological data in unified analyses evaluating the
strength of the overall body of the evidence supporting
causal connections for disease condition-outcome pairs.
Data from epidemiological studies for some central nervous
system disorders and cancer have been sparse in previous
reviews [16, 28], and recently published data could also help
to improve estimations [35–40]. Therefore, we consider it
timely to update and expand on previous meta-analyses
examining the inverse and direct cancer comorbidity in
people with central nervous system disorders.
We will perform an umbrella review of systematic
reviews and conduct updated meta-analyses of observa-
tional studies in order to synthesize all the available
epidemiological evidence and evaluate the validity of the
associations between central nervous system disorders
and the risk of developing or dying from cancer.
Methods
This protocol has been registered within the PROSPERO
database for systematic reviews and meta-analyses
(registration number: CRD42016052762). The protocol
has been designed and reported in accordance with the
reporting guidance provided in the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
Protocols (PRISMA-P) statement [41, 42] (see PRISMA-P
checklist in Additional file 1).
Design
We will conduct an umbrella review of systematic
reviews and meta-analyses of observational studies in 12
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central nervous system disorders (including Alzheimer’s
disease, anorexia nervosa, amyotrophic lateral sclerosis,
autism spectrum disorders, bipolar disorder, depression,
Down’s syndrome, epilepsy, Huntington’s disease,
multiple sclerosis, Parkinson’s disease and schizophrenia)
that reported the risk of developing or dying from any
cancer or specific types of cancer. An umbrella review is
a systematic collection and assessment of multiple
systematic reviews and meta-analyses done on a specific
research topic [33, 34, 43–46].
Participants/population
Our review targets all human participants (regardless of
age or sex) available from observational studies irre-
spective of setting (inpatient, outpatient or mixed com-
munity setting). For participants with a central nervous
disorder, we will use investigator-reported definitions
according to accepted diagnostic criteria (e.g. ninth or
tenth revisions of the International Classification of
Diseases (ICD) or the third or fourth edition of the Diag-
nostic and Statistical Manual of Mental Disorders
(DSM) criteria). Eligible central nervous system disor-
ders will be Alzheimer’s disease (ICD-9: 331.0, 290.1;
ICD-10: F00, G30), anorexia nervosa (ICD-9: 307.1,
307.54; ICD-10: F50.0-F50.1), amyotrophic lateral
sclerosis (ICD-9: 335.20; ICD-10: G12.2), autism
spectrum disorders (ICD-9: 299.0, 299.8; ICD-10: F84),
bipolar disorder (ICD-9: 296-296.16, 296.4-296.99,
301.1-301.13; ICD-10: F06.3-F06.34, F30-F31.9, F34.0),
major depression (ICD-9: 296.2-296.36, 311-311.9,
V11.1, V11.2; ICD-10: F32-F33.9), Down’s syndrome
(ICD-9: 758.0; ICD-10: Q90), epilepsy (ICD-9: 345-
345.91; ICD-10: G40-G41.9, Z82.0), Huntington’s disease
(ICD-9: 294.1, 333.4; ICD-10: F02.2, G10), multiple
sclerosis (ICD-9: 340-340.9; ICD-10: G35-G35.9),
Parkinson’s disease (ICD-9: 332-332.9; ICD-10: G20-
G21.0, G21.2-G22.0) and schizophrenia (ICD-9:
295-295.95, 301.0, 301.2-301.22, V11.0; ICD-10: F06.2,
F20-F23.9, F25-F29.9). Exclusion criteria will be animals,
in vitro and in vivo experiments.
Study outcomes
The primary outcomes will be cancer incidence and can-
cer mortality (all malignant neoplasms; ICD-9: 140-209;
ICD-10: C00-C97) in association with a specific central
nervous system disorder (as defined above—see the
‘Participants/population’ section). Secondary outcome
measures will be site-specific cancer incidence and site-
specific cancer mortality studied in association with a
specific central nervous system disorder. Following the
Global Burden of Disease Cancer Collaboration system
classification [47], site-specific cancer will be defined in
groups that include ICD codes pertaining to neoplasms
(see Additional file 3).
Types of study to be included
The types of study to be included are systematic reviews,
meta-analyses and observational studies (case-control and
cohort) in humans that examined the association between
central nervous system disorders and risk of developing or
dying from cancer. Randomized controlled trials are
unavailable for our research question. We will exclude
studies in which central nervous system disorders were
not the exposure of interest and cancer incidence or mor-
tality was not the outcome of interest. Systematic reviews,
meta-analyses and observational studies that did not
present study specific data (e.g. relative risks or odds ratios
with 95% confidence intervals and number of cases of
cancer/population) will be also excluded. We will not
apply any year, language, or publication status restrictions
in the selection of eligible studies.
Search methods
We will systematically search PubMed/MEDLINE,
EMBASE, SCOPUS and Web of Science to identify
systematic reviews and meta-analyses of observational
studies examining associations between cancer and
central nervous system disorders.
The final search strategies will be defined by a senior in-
formation specialist and a clinical epidemiologist.
Keywords related to central nervous system disorders,
cancer and systematic reviews will be used. A draft search
strategy for PubMed/MEDLINE database has been in-
cluded in Additional file 2. A manual review of references
from eligible systematic or narrative reviews will be also
performed. In addition, the online databases will be
checked for eligible observational studies that have been
published outside the time frames of previous reviews. In
particular, PubMed/MEDLINE will be searched to identify
other additional observational studies using a compiled
list of the unique PubMed/MEDLINE identification num-
bers of all relevant articles, and a related article search will
be performed. This technique has been shown to be
effective in identifying relevant studies, increases efficiency
in study identification in the presence of an already large
evidence base [48] and is being used as part of complex
evidence syntheses [49–51]. We will also contact authors
of primary publications and/or collaborators to check if
they are aware of any studies we may have missed. For
disease-outcome pairs where no systematic reviews are
available, we will conduct a new systematic search of
literature that will be prospectively reported in a new spe-
cific protocol, following standard methods described in
this paper. Any amendments or modifications made in the
protocols will be outlined and reported in the final papers.
Screening and selection procedure
Two reviewers will screen all articles identified from the
search independently. First, titles and abstracts of
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articles returned from initial searches will be screened
based on the eligibility criteria outlined above. Second,
full texts will be examined in detail and screened for
applicability. Third, references of all considered articles
will be hand-searched to identify any relevant report
missed in the search strategy. Any disagreement between
reviewers will be resolved by discussion to meet a
consensus.
Data collection process
From each eligible systematic review and meta-analysis,
two reviewers will extract information independently on
first author, year of publication, central nervous system
disorder(s) and outcome(s) examined, number of in-
cluded studies, reported summary meta-analytic esti-
mates (including heterogeneity measures), additional
analyses (e.g. subgroup analysis, meta-regression, sensi-
tivity analysis) and bias assessment (e.g. quality or risk of
bias of each study and publication bias). For each of the
included observational studies, two reviewers will also
extract the epidemiological design (cohort or case-
control, prospective or retrospective), the country of
study, the follow-up period, the setting (mixed, inpatient,
outpatient or community), coverage (multi-center or
single-center study), the general characteristics of partic-
ipants (age, sex and ethnicity), the sample size, the
outcomes of interest (including definitions and
confounding factors that were taken into consideration),
the number of cases and controls (in case-control
studies) or the number of cases and population partici-
pants (in cohort studies) and/or the maximally adjusted
relative risk (reported as odds ratio for case-control
studies and hazard ratio or standardized incidence/mor-
tality ratio for cohort studies) and 95% confidence inter-
vals. We will use pre-designed forms that will be piloted
initially on a small number of included reviews and
observational studies. We will also contact authors of
primary publications and/or collaborators for missing
outcome data or unclear information.
Quality and risk of bias assessment
The methodological quality and bias of reviews will be
appraised using the Assessment of Multiple Systematic
Reviews (AMSTAR) tool [52]. This tool consists of 11
items and has good face and content validity for measur-
ing the methodological quality of systematic reviews.
Each item within the instrument can receive 1 point, for
a possible range of AMSTAR scores of 0 to 11. The
AMSTAR instrument will be administered independ-
ently by two reviewers, and discrepant scores will be
resolved by discussion and consensus.
The methodological quality and bias of primary epi-
demiological studies will be appraised using the Newcastle
Ottawa Scale (NOS) for observational (e.g. cohort and
case-control) studies [53]. Using the NOS tool, each study
is judged on eight items, categorized into three groups:
the selection of the study groups, the comparability of the
groups and the ascertainment of either the exposure or
outcome of interest for case-control or cohort studies,
respectively. Stars are awarded for each quality item, and
the highest quality studies are awarded up to nine stars.
We will consider studies with 0–3, 4–6 and 7–9 stars to
represent high, moderate and low risk of bias, respectively.
The risk of bias for each observational study will be inde-
pendently assessed by two reviewers. Discrepant scores
will be resolved by discussion and consensus.
Methods for evidence synthesis
The data from each systematic review’s characteristics
and findings based on methodological quality will be
used to build evidence tables. The data extracted and
summarized will include specific details about the
research question, search strategy, eligibility criteria,
population (sample size and participant characteristics),
studies (type and number), methods and outcomes of
significance to the review question and results reported
in previous reviews. We will not conduct a meta-analysis
of systematic reviews in this umbrella review. Pooling
the results of the included reviews is likely to introduce
potential biases as it will give too much statistical power
to primary observational studies included in more than
one review, with the risk that a misleading estimate will
be produced and that this will be overly precise [54]. In-
stead, data from primary observational studies (primary
studies from previous reviews with new studies) will be
used to perform updated meta-analyses. We will
estimate the summary effect size and its 95% confidence
interval using the inverse variance method based on the
DerSimonian and Laird random-effects model [55]. The
random-effects model is selected a priori to synthesize
the epidemiological data, as it considers both within-
study and between-study variation by incorporating the
heterogeneity of effects into the overall analyses. If
primary studies report results separately for men and
women or other subgroups, we will combine the
subgroup-specific estimates using a fixed-effects model
to generate an estimate for both subgroups combined so
that each study was represented only once in the ana-
lyses. We will evaluate heterogeneity by estimating the
variance between studies using Cochran’s Q test [56]
and I2 statistic [57]. The Cochran Q test is obtained by
the weighted sum of the squared differences of the
observed effect in each study minus the fixed summary
effect. The I2 statistic is the ratio of variance between
studies over the sum of the variances within and be-
tween studies and ranges between 0 and 100% (with
values of 0–25%, 25–50%, 50–75% and 75–100% taken
to indicate low, moderate, substantial and considerable
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heterogeneity, respectively). We will also estimate the
95% prediction interval [58, 59], which further accounts
for between-study heterogeneity and evaluates the
uncertainty for the effect that would be expected in a new
observational study addressing that same association.
As a further important improvement over previous re-
views and meta-analyses, we will apply a set of criteria to
conclude whether the evidence for a given outcome may
be considered convincing, probable, limited-suggestive,
limited-not conclusive or unlikely. For this, we will follow
the Global Burden of Disease Study approach [60, 61]
using the World Cancer Research Fund (WCRF)/American
Institute for Cancer Research (AICR) criteria for grading
evidence [62]. ‘Convincing evidence’ consists of biologically
plausible associations between exposure and outcome
established from multiple epidemiological studies in differ-
ent populations. Evidentiary studies must be substantial,
must include prospective observational studies and, where
relevant, randomized controlled trials of sufficient size,
duration and quality and must show consistent effects. A
convincing relationship should be robust enough to be
highly unlikely to be modified in the foreseeable future as
new evidence accumulates. ‘Probable evidence’ is similarly
based on epidemiological studies with consistent associa-
tions between exposure and outcome, but shortcomings in
the evidence exist, such as insufficient trials or prospective
observational studies available. ‘Limited-suggestive evi-
dence’ represents too limited evidence to permit a probable
or convincing causal judgement, but where there is
evidence suggestive of a direction of effect. ‘Limited-not
conclusive evidence’ consists of information that is so lim-
ited that no firm conclusion can be made for a number of
reasons (e.g. the evidence might be limited by the amount
of evidence in terms of the number of studies available, by
inconsistency of direction of effect, by poor quality of
studies or by any combination of these factors). ‘Substantial
effect on risk unlikely’ consists of evidence strong enough
to support a judgement that a particular exposure is
unlikely to have a substantial causal relation to a cancer
outcome. The evidence should be robust enough to be
unlikely to be modified in the foreseeable future as new evi-
dence accumulates [60–62].
We will also use the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
methodology for evaluating the quality of evidence for
each outcome [63]. GRADE rating will be adjudicated as
high (further research is very unlikely to change our
confidence in the estimate of effect), moderate (further
research is likely to have an important impact on our
confidence in the estimate of effect and may change the
estimate), low (further research is very likely to have an
important impact on our confidence in the estimate of
effect and is likely to change the estimate) or very low
(very uncertain about the estimate of effect).
Additional analyses
Using random-effects meta-analyses, we will present
combined effect sizes estimates for the cluster of neurode-
generative disorders (including Alzheimer’s disease, amyo-
trophic lateral sclerosis, Huntington’s disease, multiple
sclerosis and Parkinson’s disease) taking into consider-
ation the growing evidence suggesting that cancer and
neurodegenerative diseases share genes and biological
pathways—the neurodegeneration hypothesis [16, 27, 28].
If sufficient studies are identified, potential sources of
heterogeneity will be investigated further by subgroup or
meta-regression analyses according to baseline charac-
teristics and methodological factors. We plan to conduct
subgroup analyses by sex (men or women), study design
(cohort or case-control; prospective or retrospective),
follow-up (0–1, >1–5 or >5 years), setting (mixed,
inpatient, outpatient or community), population based
(yes or no), country economic status (developed or
developing countries according to International Monetary
Fund), year of publication (before 2000 or in 2000 and
after), study quality (high or low-moderate risk of bias),
adjustment for confounders (age, sex or other) and sample
size (<500, 500–1000 or >1000 participants). If feasible,
we will conduct not only a subgroup analysis by ethnicity
(Asian or non-Asian) but also meta-regression analyses to
investigate the potential impact of ethnic differences [39]
by considering the percentage of Asian participants in epi-
demiological studies. We will conduct not only subgroup
analyses for cancer types according to relationship with
smoking (smoking-related cancer sites or other cancer
sites) (see Additional file 3) but also meta-regression
analyses considering the percentage of smokers (e.g. past
or current smoker).
In order to further assess the consistency of evidence,
we will perform cumulative meta-analyses in the order
of publication year showing the pattern of evidence over
time [64, 65]. Cumulative meta-analyses recognize the
cumulative nature of scientific evidence and knowledge.
Publication bias or small study effects will be assessed by
inspection of the funnel plots for asymmetry and with
Egger’s test [66] and Begg’s test [67], with the results consid-
ered to indicate potential small study effects when P < 0.10.
Software considerations
All analyses will be conducted in Stata version 13 or
higher (StataCorp LP, College Station, TX, USA) using
the metan (for fixed and random-effects meta-analysis),
metareg (for meta-regression analysis), metacum (for
cumulative meta-analysis) and metabias and metafunnel
(for small study effects analysis) [68].
Discussion
Evaluating and understanding the complex connections
between cancer and central nervous system disorders
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might be of great importance for biomedical research,
education, clinical practice and public health given
the high burden of these disease conditions worldwide
[1–5]. This review will establish the extent of the
epidemiological evidence underlying the associations
between central nervous system disorders and the risk
of developing or dying from cancer. This protocol
updates and will supersede previous meta-analyses of
observational studies on this topic [16] and will pro-
vide a rigorous and updated synthesis of a range of
important site-specific cancer outcomes. Any amend-
ments made to this protocol when conducting the
review will be outlined and reported in the final paper.
There are several strengths and limitations of our
planned methods. We will comprehensively review and
evaluate a significant amount of epidemiological data
characterizing the associations between central nervous
system disorders and cancer. Beyond summarizing the
findings for a wide range of central nervous system
disorders and cancers, we will explore the extent of bias
and heterogeneity in the observational research. Further-
more, we anticipate that some outcomes will be poorly
covered in the scientific literature, and thus, knowledge
gaps will be identified. Our findings could potentially be
useful not only for informing a research agenda of new
epidemiological studies that can be linked to large
world-class consortiums of scientists and researchers
conducting prospective studies and meta-analyses but
also for educational and training opportunities. A limita-
tion is that based on knowledge from previous reviews,
we anticipate identifying not only studies using different
study designs, populations and outcome definitions
(which may increase statistical heterogeneity in the
potential associations) but also a lack of complete report-
ing of methods and results in some epidemiological
studies [69–71]. Further, the possibility of selective out-
come reporting bias in cancer epidemiology [30–34] could
also be a potential limitation.
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